Clinical trials: in Venezuela
Breast Cancer
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a…
- Trial name
- CONFIRM (NCT00099437)
- Testing
- Fulvestrant
- Where
- 106 sites in United States, Belgium and 15 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Poor Ovarian Response, Female Infertility of Other Origin
Exosome-Enriched Culture Media to Enhance In Vitro Maturation and Embryo Development in Poor Ovarian Responders Undergoing IVF
Evaluating the Efficacy of Exosome-Enriched Culture Media to Enhance In Vitro Maturation and Embryo Development in Poor Ovarian Responders Undergoing IVF Summary: This is a prospective, randomized controlled trial designed to…
- Conditions
- Poor Ovarian Response, Female Infertility of Other Origin, Oocyte Immaturity
- Trial name
- EXOMAT (NCT07085312)
- Testing
- Exosome-Enriched IVF Culture
- Where
- Venezuela
- Volunteers
- 10 people
- Sponsor
- Fertiaguerrevere
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Aortic Stenosis
transShield Embolic Protection System Feasibility Study
The objective of this study is to evaluate the safety and performance of the transShield Embolic Protection System (EPS) used for embolic protection during Transcatheter Aortic Valve Replacement (TAVR).
- Trial name
- NCT04585308
- Testing
- transShield Embolic Protection System
- Where
- 4 sites in New Zealand, Venezuela
- Volunteers
- 28 people
- Sponsor
- TransAortic Medical, Inc.
Breast Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC)…
- Trial name
- NCT01702571
- Testing
- Trastuzumab Emtansine
- Where
- 300 sites in Argentina, Australia and 41 more
- Volunteers
- 2,185 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Bipolar Mania, Bipolar Disorder
Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8…
- Trial name
- NCT00280566
- Testing
- Ziprasidone Oral Capsule
- Where
- 107 sites in United States, Chile and 11 more
- Volunteers
- 584 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Abdominal Aortic Aneurysms
The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms
The purpose of this clinical study is to evaluate the safety and device performance of the Nellix® EndoVascular Aneurysm Sealing System (Nellix System) for the treatment of infrarenal abdominal aortic aneurysms.
- Trial name
- NCT02048514
- Testing
- The Nellix® EndoVascular Aneurysm Sealing System
- Where
- 4 sites in Colombia, Latvia and 2 more
- Volunteers
- 69 people
- Sponsor
- Endologix
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
- Trial name
- LA ATGOAL (NCT00645151)
- Testing
- Atorvastatin
- Where
- 33 sites in Brazil, Chile and 6 more
- Volunteers
- 512 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.
- Trial name
- NCT00333866
- Testing
- pregabalin
- Where
- 74 sites in Australia, Canada and 14 more
- Volunteers
- 747 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Seizures
Pregabalin Versus Levetiracetam In Partial Seizures
This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.
- Trial name
- NCT00537238
- Testing
- pregabalin, levetiracetam
- Where
- 72 sites in Belgium, Bulgaria and 19 more
- Volunteers
- 509 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypercholesterolemia
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
- Trial name
- CRUCIAL (NCT00407537)
- Testing
- Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 125 sites in Costa Rica, Croatia and 18 more
- Volunteers
- 1,531 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathy, Painful
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
- Trial name
- NCT00156078
- Testing
- pregabalin
- Where
- 35 sites in Argentina, Brazil and 17 more
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bone Neoplasms, Pain, Intractable
A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer
The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.
- Conditions
- Bone Neoplasms, Pain, Intractable, Cancer
- Trial name
- COPE (NCT00381095)
- Testing
- Pregabalin
- Where
- 55 sites in United States, Canada and 17 more
- Volunteers
- 152 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes Mellitus, Type 2
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
- Trial name
- NCT00860288
- Testing
- Vildagliptin, Metformin, Sitagliptin
- Where
- 187 sites in Argentina, Austria and 19 more
- Volunteers
- 1,988 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack.
- Trial name
- EMPHASIS-HF (NCT00232180)
- Testing
- Eplerenone
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 2,743 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myelogenous Leukemia, Chronic
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+)…
- Trial name
- ENESTnd (NCT00471497)
- Testing
- nilotinib, imatinib
- Where
- 213 sites in United States, Argentina and 33 more
- Volunteers
- 846 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche